Company

Triumvira Immunologics, Inc.

Triumvira Immunologics, founded in 2015 in Austin, develops cancer immunotherapies based on its TAC technology.

About

Founded in 2015 in Austin, US, Triumvira Immunologics develops immunotherapies built on its proprietary T cell Antigen Coupler (TAC) technology, which helps T cells recognize a range of cancer antigens. Its flagship candidate, TAC101-CLDN18.2, targets Claudin 18.2 in advanced solid tumors. The company raised USD 9.01 million in Series A funding on March 17, 2022, led by B Capital Group, with participation from ATEM Capital and Myeloma Investment Fund. CEO Paul Lammers leads the company, and Jonathan Bramson is the founder.

2Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in